According to InvestingPro analysis, GSK maintains a "GREAT" financial health score, positioning it well for continued pharmaceutical innovation. If approved, depemokimab would be the first ultra ...

GSK's depemokimab gets EMA nod for asthma and nasal polyps. 2mo. G SK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements.

More on GSK's Depemokimab Development Plans. Earlier this year, two phase III studies namely — SWIFT-1 and SWIFT-2 — which evaluated depemokimab for treating severe asthma characterized by ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials.. The ANCHOR ...

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise in reducing nasal polyp growth and obstruction. Full results to be ...

GSK has projected depemokimab to generate close to $4 billion in yearly revenue if approved. The long-acting molecule could require a dose just every six months to treat CRSwNP, ...

GSK, a UK-based biopharma, reported strong 2024 results, ... So, just with Blenrep and Depemokimab, GSK already has the potential to grow its revenues by another extra £7 billion.

Depemokimab, GSK’s long-acting, anti-interleukin (IL)-5 monoclonal antibody (mAB), is currently under review as an add-on maintenance treatment for asthma in paediatric ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with ...